AstraZeneca Plc (NASDAQ:AZN) reported fourth-quarter sales of $14.89 billion, up 18% year over year (+19% at constant ...
The Committee for Medicinal Products for Human Use (CHMP) has recommended that the immunotherapy be approved to treat adults ...
Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...
The boss of AstraZeneca has denied a rift with the Government after axing plans for a £450m vaccine factory in Liverpool ...
Imfinzi has been recommended for approval in the European Union, EU, as monotherapy for the treatment of adults with ...
AstraZeneca ‘very disappointed’ after ditching £450m Liverpool vaccine site - Pascal Soriot, chief executive of AstraZeneca, ...